Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis and Bayer finalise Betaferon manufacturing agreement

Novartis and Bayer finalise Betaferon manufacturing agreement

14th September 2007

Novartis and Bayer Schering Pharma have announced the completion of a deal between the firms relating to multiple sclerosis drug Betaferon (interferon beta-1b).

Under the terms of the agreement, Bayer has paid Novartis the sum of $200 million (98.6 million pounds), with Bayer acquiring a biologics manufacturing facility in Emeryville, California.

Furthermore, Bayer has received production equipment, inventory and use of the buildings at the site and will retain full control over the manufacturing of the compound.

“Bayer Schering Pharma will continue to pay Novartis royalties equivalent to those being paid currently on net sales of Betaseron [Betaferon] manufactured by Bayer at the Emeryville facilities until expiration of the original regulatory filing, development and supply agreement in October 2008,” Bayer reports.

It adds that no further royalties on sales of Betaferon will be paid to Novartis after this date.

Additionally, Novartis will be supported by Bayer in its regulatory filing for a 250mcg formulation of the drug, with Bayer to supply the drug to Novartis from 2009 in exchange for a double-digit royalty payment on sales.

Last month, Bayer reported the publication of a “landmark” Betaferon study in the Lancet journal, with patients showing a first clinical multiple sclerosis event administered with Betaferon exhibiting a 40 per cent reduced risk of developing a confirmed disability.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.